



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/506,805	01/19/2005	Andrew Lennard Lewis	Q83534	5416
23373	7590	10/29/2008		EXAMINER
SUGHTRUE MION, PLLC				PURDY, KYLE A
2100 PENNSYLVANIA AVENUE, N.W.			ART UNIT	PAPER NUMBER
SUITE 800			1611	
WASHINGTON, DC 20037				
			MAIL DATE	DELIVERY MODE
			10/20/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Application No.	Applicant(s)
10/506,805		LEWIS ET AL.	
Examiner	Art Unit		
Kyle Purdy	1611		

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 08/31/2007, 01/11/2008 and 08/06/2008.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-5,16,20-35,38 and 42-56 is/are pending in the application.
 4a) Of the above claim(s) 29-35 and 45-56 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1,5-16,20-28,38 and 42-44 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____

5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

Response to Restriction Requirement

1. Applicant's election of Group I in the reply filed on 08/06/2008 is acknowledged.

Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). This requirement is deemed proper and made final.

Status of Application

2. The Examiner acknowledges receipt of the amendments filed on 08/06/2008 wherein claim 1 has been amended and claims 2-4 and 37 have been cancelled.
3. Claims 1, 5-28, 38 and 42-44 are presented for examination on the merits. The following rejections are made.

Response to Applicants' Arguments

4. Applicants arguments filed 08/06/2008 regarding the rejection of claim 1, 4-14, 20-25, 38 and 42-44 made by the Examiner under 35 USC 102(b) over Lobb et al. (J. Am. Chem Soc., 2001) have been fully considered and they are found persuasive. This rejection is withdrawn as being overcome by amendment.
5. Applicants arguments filed 08/06/2008 regarding the rejection of claims 2, 3, 28 and 37 made by the Examiner under 35 USC 103(a) over Lobb et al. (J. Am. Chem. Soc., 2001) in view of Konno et al. (Biomaterials, 2001) have been fully considered and they are found persuasive. This rejection has been overcome by cancellation of claims and amendment.
6. Applicants arguments filed 08/06/2008 regarding the rejection of claims 15, 26 and 27 made by the Examiner under 35 USC 103(a) over Lobb et al. (J. Am. Chem. Soc., 2001) have

been fully considered and they are found persuasive. This rejection has been overcome by amendment.

7. Applicants arguments filed 08/06/2008 regarding the rejection of claims 20 and 42 made by the Examiner under 35 USC 103(a) over Lobb et al. (J. Am. Chem. Soc., 2001) in view of Cossens et al. (Prog. Polym. Sci., 2001) have been fully considered and they are found persuasive. This rejection has been overcome by amendment.

New Grounds of Rejections, Necessitated by Amendment
Claim Rejections - 35 USC § 103


8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

9. Claims 1, 5-16, 21-28, 38, 43 and 44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lobb et al. (J. Am. Chem. Soc., 2001, 123, 7913-7914; of record) in view of Kataoka et al. (Adv. Drug Delivery Rev., 2001, 47(1), 113-131), evidenced by Dalmark et al. (J. Gen. Physiol, 1981, 78, 349-364).


10. Lobb discloses the synthesis of a biocompatible phosphorylcholine-based methacrylate copolymer. The copolymer is an amphiphilic block copolymer having a hydrophilic block and in the solution, and a biologically active compound associated with the polymer [fibrinogen] (see page 7914, left column 2nd paragraph; see instant claim 1), wherein the hydrophilic block has pendant zwitterionic groups (see Figure 2; structure; see instant claim 1). The copolymer is in the form of micelles (see Figure 2, 'DEA core micelles'; see instant claim 1). The hydrophilic block

is formed by radical polymerization of the ethylenically unsaturated monomers (see page 7913, left column, 2nd paragraph; see instant claim 5). The hydrophilic monomers comprise a zwitterionic monomer having the following structure:



(see Figures 1 and 2; see instant claim 6-12 and 38).

11. The hydrophobic block comprises a pendant group which is ionizable and possesses a pKa or pKb in the range of 4 to 10 (see Figure 2, structure). The hydrophobic structure is shown below:



12. The pKa for the hydrophobic structure is 9.17 (see STN search of structure b; see instant claim 13). The hydrophobic block is polymerized by radical polymerization of the ethylenically unsaturated monomers (see page 7914, left column, 4th paragraph; see instant claim 14). The degree of polymerization for the hydrophilic block is 30 (see Figure 2, structure; see instant claims 21 and 43) and the degree of polymerization for the hydrophobic block is 100 (see Figure 2, structure; see instant claims 22 and 44). The ratio for the degrees of polymerization is 10:3 which falls within the range of 1:5 to 10:1 (see Figure 2, structure; see instant claim 23). The polymerization process for polymerizing the hydrophilic block is via atom transfer radical

polymerization (see page 7913, left column, 2nd paragraph; see instant claims 24-25). Lobb teaches that the atom transfer radical polymerization initiator is that of oligo(ethylene glycol) bromide (OEGBr). OEGBr is a hydrophobic polymer compound and is taught to be used for the synthesis of the MPC homopolymer (see page 7913, right column, 2nd paragraph; see instant claim 26). It is also taught that that MPC diblock copolymers can also be synthesized via atom transfer radical polymerization (see page 7914, left column, 4th paragraph; see instant claims 24 and 25). Moreover, Lobb suggests that the polymeric micelles are highly biocompatible and show considerable promise for drug delivery applications (see 7914, right column).

13. Lobb fails to specifically teach the species of diisopropylamino ethyl phosphate inner salt. Lobb also fails to teach the nanoparticle as having a hydrophobic drug associated with the core of the nanoparticle, said nanoparticle having a partition coefficient between octanol and water of at least 1.5.

14. Kataoka is a review article directed to block copolymer micelles and their use in local drug delivery. In the abstract it is taught that block copolymers are useful because of the fact that the outer hydrophilic surface can be functionalized to optimize its physicochemical and biological properties whereas the inner hydrophobic core is useful as a functioning reservoir for a variety of diverse drugs. It is also taught that much interest has been directed to loading nanoparticles with drugs because of the relatively high loading capacity of the inner core (see page 114, left column.) In section 2, an example of an amphiphilic copolymer micelle is taught wherein the micelles hydrophobic core houses the cytotoxic drug doxorubicin (see page 115). Doxorubicin has a partition coefficient between water and octanol of 1.9 (see Dalmark et al., page 356; see instant claim 1) It is taught that significant pi-pi interactions contribute substantially to

increasing the cohesive force in the core which stabilizes the physically entrapped drug (see page 116, left column).

15. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings of Lobb and Kataoka with a reasonable expectation for success in arriving at a composition comprising an amphiphilic copolymer having a zwitterionic group which has a biologically active, cytotoxic molecule with a partition coefficient of at least 1.5 sequestered in the core of the micelle. One would have been motivated to substitute diisopropylamino ethyl methacrylate for (diethylamino)ethyl methacrylate because the two monomers only differ by the presence of a methyl group. The presence of a methyl group in place of a hydrogen does not give patentable momentum to the recited species. It is well established that a methyl is structurally analogous to a hydrogen, and absent any secondary result, the elected species would possess the same functional properties as that of diethylammonium. With respect to including the drug within in the core of the particle, this is also obvious. Kataoka specifically teaches that loading hydrophobic cytotoxic drugs which have a partition coefficient of at least 1.5 into their core is a common practice in the art of amphiphilic micelles. One would be motivated to employ the structure discussed by Kataoka because of the ability to achieve high loading of drug into the particle which means high localized dosages to the patient. Moreover, by loading the drug into the core of the micelle, the drugs rate of release will be controlled and the drug will provided a thermodynamically stable environment. With respect to the requirement that the copolymer be synthesized by an initiator (e.g. OEGBr) possessing a hydrophobic polymer moiety is also obvious, as it is specifically suggested by Lobb. Therefore, the invention as a whole is *prima facie* obvious to one of ordinary skill in the

art at the time the invention was made, as evidenced by the references, especially in absence of evidence to the contrary.

16. Note, Dalmark is cited as to show that doxorubicin has a partition coefficient between octanol and water of at least 1.5.

17. **Claims 20 and 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lobb et al. (J. Am. Chem. Soc., 2001, 123, 7913-7914; of record) in view of Kataoka et al. (Adv. Drug Delivery Rev., 2001, 47(1), 113-131) and Coessens et al. (Prog. Poly. Sci., 2001, 26, 337-377; of record), evidenced by Dalmark et al. (J. Gen. Physiol, 1981, 78, 349-364).**

18. Lobb, Kataoka and Dalmark are relied upon for disclosure described in the rejection of claim 1 under 35 U.S.C. 103(a).

19. Lobb teaches that the polydispersity of the MPC homopolymer block is from between 1.23 to 1.45 (see page 7914, left column, 2nd paragraph).

20. Lobb, Kataoka and Dalmark fail to teach the polydispersity for the hydrophobic block of the copolymer.

21. Coessens cures this deficiency. Coessens is drawn to describing in detail the properties generally associated with atom transfer radical polymerization process, teaches that atom transfer radical polymerization creates well-defined, precisely controlled polymers with polydispersities generally lower than 1.3 (see Coessens, page 339, last paragraph).

22. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings of Lobb Kataoka, Coessens and Dalmark with a reasonable expectation for success in arriving at a composition comprising an amphiphilic block

copolymer having a hydrophilic and a hydrophobic block, dispersed in solution, and a biologically active compound associated with the polymer, wherein the hydrophilic block as pendant zwitterionic groups wherein the polydispersity of molecular weight of each block is from 1.1 to 1.4. Although Lobb is silent to the polydispersity of the hydrophobic block, the block if synthesized by atom transfer radical polymerization would quite likely have a polydispersity less than 1.3. Therefore, the invention as a whole is *prima facie* obvious to one ordinarily skilled in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Conclusion

23. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

24. A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

25. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kyle A. Purdy whose telephone number is 571-270-3504. The examiner can normally be reached from 9AM to 5PM.

26. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sharmila Landau, can be reached on 571-272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

27. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*/Kyle Purdy/
Examiner, Art Unit 1611
October 8, 2008*

*/Sharmila Gollamudi Landau/
Supervisory Patent Examiner, Art Unit 1611*